SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the focal point, with traders watching guidance, subscriber engagement, advertising growth, and content strategy amid leadership changes and layoffs. Bearish concerns about competition, content quality, and slowing growth contrast with bullish hopes that low expectations and ad expansion could support a positive reaction.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally and renewed attention center on traders positioning ahead of the full Phase 3 melanoma cancer-vaccine data presentation at ESMO, following previously positive topline results. Bulls see the readout as validation of a broader oncology platform, while skeptics argue the rally has outpaced the evidence and could unwind in a sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp move is drawing attention as shares push above recent technical resistance, while traders point to anticipated DM1 and FSHD siRNA data as potential catalysts. Some see strength or possible short covering, while others caution that past rallies have faded and no new catalyst is confirmed in the discussion.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are falling amid concern over plans to list its Monee financial-services arm and launch Sea Cloud, which traders worry could add spending and strategic uncertainty. The community is split between viewing a Monee separation as a potential value unlock and fearing it could weaken the remaining business, while some see the selloff as an overreaction.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and raised outlook have been met with a sharp selloff, prompting frustration and debate over why strong demand and guidance have not supported the shares. Traders point to profit-taking and elevated expectations, while cost pressures, weaker cash conversion and an insurance-unit loss have raised questions about margins and the quality of the results.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings beat and a new buyback authorization, as traders focus on narrowed full-year profit guidance with an unchanged midpoint and weaker vehicle sales. Some view the drop as overdone given the stronger cash-flow outlook and buyback, while others see the outlook as too cautious to offset the earnings-day disappointment.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention to the drugs potential and analyst optimism. Traders are debating whether the placebo-adjusted benefit is modest and whether agitation concerns and higher discontinuations could limit the upside, with some viewing the move as vulnerable to a fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving attention and a sharp rally, with traders viewing the cash proceeds as a balance-sheet and strategic reset. Others argue the divestiture removes a meaningful revenue stream and leaves concerns about debt and the remaining businesss growth unresolved.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers push to a fresh 52-week high is drawing attention, with traders celebrating a long-awaited recovery and debating whether the breakout can hold or will meet resistance. Some point to defensive-sector demand and pipeline progress, while others say the move needs a clearer company-specific catalyst.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention is centered on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel results in progressive MS, alongside new BRIUMVI data. Traders are hopeful azer-cel could add a growth opportunity beyond BRIUMVI, while recognizing the early readouts efficacy is uncertain; continued BRIUMVI sales growth is the more established part of the story.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Equity

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


Direxion Shares ETF Trust - Direxion Daily Pharmaceutical & Medical Bull 3X ETF

Neutral Sentiment

<ul class="summary-bullets"><li>Eli Lilly announced it will pay $6.75 per share in cash, with additional milestone payments tied to the development of ATAI's two lead depression therapies.</li><li>The pharma giant said the acquisition strengthens its neuroscience pipeline with two late-stage programs targeting treatment-resistant depression.</li><li>Over the past year, Compass has significantly outperformed ATAI.</li></ul>Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.Lilly stated it will acquire all outstanding ATAI shares for $6.75 per share in cash at closing, plus up to $2.50 per share tied to future development and regulatory milestones for ATAI's two lead programs, bringing total potential value to as much as $9.25 per share.&nbsp;Based on ATAI's Wednesday close of around $5.36, the $6.75 per share cash offer represents a premium of approximately 25.9%. Taking total potential consideration of $9.25 into account, the premium to Wednesday's close would be approximately 72.6%.The deal is expected to close in the third quarter (Q3), pending shareholder and regulatory approval.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/ATAI_2026_07_16_06_37_17_png_4cad859a33.webp" alt="ATAI_2026-07-16_06-37-17.png" width="2643" height="1588"><figcaption>ATAI stock historical performance vs. pre-market on July 16. | Source: TradingView</figcaption></figure><a href="https://stocktwits.com/symbol/ATAI/">ATAI stock</a> jumped over 33% in pre-market trade, paring gains from a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-atai-stock-soaring-59-after-hours/cZZPl7dR7rk">jump of around 60%</a> earlier in the day. If pre-market grains hold, ATAI’s stock is on track to hit its highest levels since December 2021 and mark the biggest single-day jump in the company’s history.<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_063534529_png_3a8bd239cd.webp" alt="koyfin_20260716_063534529.png" width="2400" height="1240"><figcaption>ATAI stock historical single-day stock price changes. | Source: Koyfin</figcaption></figure><a href="https://stocktwits.com/symbol/LLY">LLY's stock</a> was also among the top trending tickers on Stocktwits, edging higher by around 0.4% in pre-market trade.<h2 class="st-heading-2">What is Lilly Buying?</h2>ATAI's lead asset is BPL-003, an intranasal, synthetic form of 5-MeO-DMT for treatment-resistant depression that has already earned FDA Breakthrough Therapy Designation and entered Phase 3 activities, following a Phase 2b study showing rapid and durable symptom reduction after a roughly two-hour in-clinic session.&nbsp;Its second program, VLS-01, is a buccal film formulation of DMT currently in Phase 2b. "Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," said Carole Ho, Lilly Neuroscience's president.&nbsp;ATAI co-founder and CEO Srinivas Rao said the deal gives the company's pipeline "the resources and scale" to move faster than it could independently.<h2 class="st-heading-2">Why Is CMPS Stock Rallying Too?</h2><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> gained more than 7% in pre-market trade, and the move isn't purely coincidental. ATAI has historically been Compass's largest shareholder, though its stake has fallen from a peak of roughly 29% to 4.96% as of a February 2026 filing, dropping it below the 5% threshold requiring continued disclosure of its position.CMPS shares are also riding a separate, broader tailwind. Regulatory momentum for psychedelic therapies has been building steadily since President Donald Trump signed an executive order in April directing the Federal Drug Administration (FDA) to fast-track review of psychedelic drugs with Breakthrough Therapy designation.&nbsp;Earlier this week, the FDA announced a public hearing on psychedelic therapies and published final clinical guidance for developers on July 14. The Department of Health and Human Services (HHS) and the Department of Veterans Affairs also announced a new collaboration in anticipation of the first investigational drug approvals.&nbsp;<h2 class="st-heading-2">How Does Retail Feel About AtaiBeckley-Eli Lilly Deal?</h2>Retail sentiment around ATAI stock on Stocktwits rose to ‘extremely bullish’ from ‘bullish’ territory over the past day. Chatter stayed at ‘extremely high’ levels. Meanwhile, sentiment around CMPS stock fell to ‘neutral’ from ‘bullish’ territory, accompanied by chatter at ‘high’ levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_07_16_072103_png_95d0276b5f.webp" alt="Screenshot 2026-07-16 072103.png" width="1272" height="690"><figcaption>ATAI stock retail sentiment on July 16 as of 7:30 a.m. ET | Source: Stocktwits&nbsp;</figcaption></figure>Retail traders on the platform expressed excitement about what the takeover could mean for AtaiBeckley’s future growth.<stembedurl>https://www.stocktwits.com/LoadedUP1000/message/659184838</stembedurl><h2 class="st-heading-2">Comparing The Fundamentals</h2>The two companies sit at different stages of development. ATAI’s stock carries a ‘Strong Buy’ rating from two analysts, and a ‘Buy’ rating from 12 out of the 14 analysts covering the stock, according to Koyfin data. The average price target for the shares is around $14.17, and a trailing one-year return of about 102%.Wall Street was similarly bullish on Compass as well. CMPS Stock carries a ‘Strong Buy’ rating from three analysts and a ‘Buy’ rating from 12 out of the 15 analysts covering the stock. The average price target for the shares is around $24.47, implying a roughly 84% potential upside from Wednesday's close.Neither company currently generates meaningful revenue. Compass has posted essentially $0 in quarterly sales across every quarter tracked since early 2025, reflecting its status as a clinical-stage company with no approved products yet. Consensus estimates project continued losses, including a projected adjusted loss of $0.31 per share for the quarter ending June 30.&nbsp;ATAI shows a similar profile, with quarterly sales in the range of just $0 to $2 million and a projected adjusted loss of $0.11 per share for the same period.Over the past year, Compass has significantly outpaced ATAI since mid-April, gaining nearly 93% year-to-date versus ATAI's roughly 31%<figure class="image"><img src="https://news.stocktwits-cdn.com/koyfin_20260716_061620094_png_c1a394bb97.webp" alt="koyfin_20260716_061620094.png" width="2400" height="1240"><figcaption>CMPS stock vs. ATAI stock performance year-to-date. | Source: Koyfin</figcaption></figure>Unlike ATAI, which will now become part of Eli Lilly, Compass remains an independent, publicly traded company focused on developing psychedelic therapies for treatment-resistant mental health conditions.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-says-53-b-offer-for-pay-pal-is-simply-too-low/cZZPR3LR7Ai">Michael Burry Says $53B Offer For PayPal Is 'Simply Too Low' – ‘The Big Short’ Investor Expects Higher Bid</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Eli Lilly logo on modern glass office building facade with partly cloudy sky, South San Francisco, California, October 16, 2025. (Photo by Smith Collection/Gado/Getty Images)

Shares of AtaiBeckley Inc. (ATAI) and Compass Pathways (CMPS) surged in pre-market trade on Thursday, and both were among the top-trending tickers on Stockwits after Eli Lilly (LLY) confirmed it is acquiring AtaiBeckley.

AtaiBeckley Inc.

COMPASS Pathways

Lilly(Eli) & Co

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

AdvisorShares Psychedelics ETF

SPDR Pharmaceuticals ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Feed

News

Sentiment

Fundamentals

Info

PILL Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Fundamentals

Latest PILL News